Posts by VIVA! Communications
Cochrane review pours cold water on heart protective benefits of fish oil
A recently published Cochrane review has poured cold water on the value of smelly fish oil preparations. Despite long being touted as a “miracle food” for their alleged cardio-protective benefits, Australia’s most commonly taken supplement does nothing to reduce cardiovascular events, coronary heart deaths, stroke or even heart irregularities. The analysis examined evidence from almost…
Read MoreThe science & prescribing of medicinal cannabis
Three leading integrative medicine bodies will unite in Sydney next month (September 8 – 9) to educate Australian practitioners on the science and prescribing of medicinal cannabis. The 2-day-long, RACGP accredited event will focus on clinical applications, patient safety and local regulations for the prescribing of medicinal cannabis. According to event organisers – the National…
Read MoreSimple blood test to detect early stage melanoma on horizon
Aussie researchers have developed the world’s first blood test to detect early stage melanoma. Researchers from Edith Cowan University (ECU), Perth produced the test after examining more than 1,600 functional proteins and identifying 10 auto-antibodies associated with melanoma. Early detection of melanoma is associated with an 80 – 95% survival rate. The blood test, which…
Read MoreDoctors sound alarm bell at lack of qualified nurses in aged care sector
Doctors have this week raised an alarm regarding the lack of qualified nurses working in the Australian aged care sector. According to the AMA’s most recent Aged Care survey, 35% of doctor respondents plan to stop accepting new patients, to reduce or completely cease their aged-care visits within the next two years. The survey involved…
Read MorePharmaxis granted FDA clearance to produce Aridol locally for US market
ASX-listed pharmaceutical company, Pharmaxis has today been granted FDA clearance to commence Sydney-based production of its asthma diagnostic medication, Aridol for the US. The approval follows hot-on-the-heels of the FDA’s recent inspection of the Sydney facility which manufactures Aridol for Australia, South Korea and Europe, and Bronchitol for Australia, Europe and Russia respectively. Following FDA…
Read More